HIV treatment study for people in Eastern Europe and Russia
Part of Infections clinical trials.
This study looks at how well newer HIV medicines work in people starting treatment for the first time in Eastern Europe and Russia. It also checks for drug resistance to find better treatment strategies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are starting HIV treatment for the first time with a newer type of medicine called a second-generation integrase inhibitor (like dolutegravir or bictegravir)
- You have a blood sample or HIV genetic test from before you started treatment
- You are at least 18 years old
- You agree to let your medical data be used for research (if required by local laws)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving two experimental drugs together can help your immune system find and destroy hidden HIV cells. It aims to see if this approach can reduce the amount of virus in your body even while you're on your regular HIV medications.
This is an early-stage trial testing a new experimental drug (IAP-086-1) in people with HIV who have their virus well-controlled on current medications. Researchers want to understand how safe the drug is and how the body handles it.
This study is a registry (a way to collect and organize information) for people living with HIV who have drug-resistant virus. It may help researchers better understand how resistant HIV behaves and how to manage treatment over time.
This trial is a registry for people with HIV whose virus is no longer fully controlled by certain newer medications (integrase inhibitors). It aims to collect data to better understand why these treatments stop working and how to improve future care.
This trial helps hospitals find undiagnosed HIV by improving testing and care. It supports healthcare teams to identify HIV in people with certain conditions and ensures those diagnosed get connected to treatment.
This study looks at tiny cell “messengers” in blood and stool to understand how HIV behaves before and after starting treatment. You may be eligible if you have untreated HIV (or you’re a healthy volunteer) and can commit to many sample visits, including long-term storage for 20 years.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.